Full text is available at the source.
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
Heart, kidney, and leg health in type 2 diabetes patients after artery treatment using two diabetes drug types
AI simplified
Abstract
SGLT2 inhibitors are associated with significantly lower risks of heart failure hospitalization and all-cause mortality compared to DPP4 inhibitors in patients with type 2 diabetes after percutaneous coronary intervention.
- Heart failure hospitalization occurred at a rate of 1.35% per year with SGLT2i compared to 2.28% per year with DPP4i.
- Coronary revascularization rates were 2.33% per year for SGLT2i and 3.36% per year for DPP4i.
- The risk of composite renal outcomes was significantly lower with SGLT2i (0.10% per year) than DPP4i (1.05% per year).
- All-cause mortality was 2.27% per year for SGLT2i versus 3.80% per year for DPP4i.
- No significant differences were observed in the risks of ischaemic stroke and acute myocardial infarction between the two treatment groups.
AI simplified